Chief Executive of HKSAR Visits PuraPharm
Facility in Nanning
Asia's most advanced Chinese medicine manufacturing
facility
seen as role-model for Hong Kong businesses
Hong Kong, June 2, 2006 - PuraPharm International
(HK) Ltd. was today honored by a visit to its modernized
Chinese medicine factory in Nanning by the Chief Executive
of the Hong Kong Special Administrative Region, Mr.
Donald Tsang, accompanied by local business leaders.
The factory was shortlisted for a stop on the Chief
Executive's tour, as a prime example of Hong Kong
capital investment in western China.
Mr. Fred Lam, Executive Director of Hong Kong Trade
Development Council, which organized the tour, said,
"Hong Kong needs to further diversify its manufacturing
industry and to escalate up the value chain to develop
innovative and high value-added products. Leveraging
Guangxi's resources, PuraPharm finds a unique way
of doing so."
The factory, with a capacity of 1,500 tons of concentrated
Chinese medicine extracts per year, is one of the
most sophisticated of its kind within the region and
is regarded among the best pharmaceutical production
facilities in Asia. It was built in 2004 with a total
investment of HK$200 million, incorporating the efforts
of leading architects, engineers and pharmaceutical
plant design specialists from Canada, Australia and
Japan. The company selected Guangxi as its production
base for two key reasons: firstly, the availability
and wide variety of natural/wild Chinese medicines;
and secondly, the full support of the Guangxi government
in encouraging investment from Hong Kong businesses,
including provision of policy and tax allowances.
Mr. Tsang visited all areas of the facility, from
research laboratories to raw herbs processing, quality
control and advanced production lines. In addition
to capital investment, PuraPharm has developed a variety
of pioneering proprietary technologies, such as DNA
fingerprinting for Lingzhi products, produced in collaboration
with Hong Kong Baptist University and also viewed
by the visitors.
"Our vision is to produce modernized Chinese
medicine, true to the traditional philosophy but with
all the benefits of convenience, standardization and
efficiency consumers expect from modernized medicines,"
said PuraPharm founder and Chairman, Mr. Abraham Chan.
"As one of only six approved corporations in
China to produce and market Chinese medicine granules,
and the only one headquartered in Hong Kong, we feel
it is our responsibility to continuously invest our
time and resources in the people, technologies and
products that will ultimately benefit consumers as
well as helping to ensure a vibrant economy here in
Guangxi province."
PuraPharm's modernized concentrated Chinese herbal
extract and health products are sold in Hong Kong,
Mainland China, Taiwan, Singapore, Philippines, Thailand,
United States and Canada. Well-known PuraPharm brands
include Puralin, Haveron and NONG'S concentrated Chinese
Medicine Granules.
China launched the western development program in
2000 to narrow the economic gap between the region
and the country's east. Ministry of Commerce statistics
showed that in the first two months of 2006, the western
region approved the establishment of more than 200
overseas-funded enterprises, and used US$276 million
of overseas capital, up 51% year-on-year.
About PuraPharm International (HK) Ltd
Established in 1998, PuraPharm is the fastest growing
Chinese medicine manufacturer in Hong Kong. The company's
vision is to help people live healthy and long lives,
through the modernization of Chinese medicine and
continual scientific research, promoting the wisdom
of traditional Chinese medicine and providing more
convenient and effective Chinese medicine products.
Headquartered in Hong Kong, the company has branches
in China, Taiwan, Singapore, Thailand, Philippines,
United States and Canada.
Photo Captions
|